Product nameAnti-CRELD1 antibody
See all CRELD1 primary antibodies
DescriptionRabbit polyclonal to CRELD1
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Horse, Cow, Dog, Pig, Chimpanzee, Macaque monkey, Gorilla, Orangutan
Synthetic peptide corresponding to Human CRELD1 aa 100-200 conjugated to keyhole limpet haemocyanin.
Database link: Q96HD1
- This antibody gave a positive result in IHC in the following FFPE tissue: Human heart muscle. This antibody also gave a positive signal within WB in the following tissue lysates: Human Fetal Heart; Human Heart; Mouse Heart; Rat Heart.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab131286 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 45 kDa (predicted molecular weight: 45 kDa).|
|IHC-P||Use a concentration of 5 µg/ml.|
Tissue specificityHighly expressed in fetal lung, liver, kidney, adult heart, brain and skeletal muscle. Weakly expressed in placenta, fetal brain, and adult lung, liver, kidney and pancreas.
Involvement in diseaseDefects in CRELD1 may be the cause of susceptibility to atrioventricular septal defect type 2 (AVSD2) [MIM:606217]. AVSD is a spectrum of cardiac malformations that result in a persistent common atrioventricular canal. The complete form of AVSD involves underdevelopment of the lower part of the atrial septum and the upper part of the ventricular septum. A less severe form, known as partial AVSD or ostium primum atrial septal defect has a deficiency of the atrial septum. Complete AVSD are clinically apparent at birth, whereas less severe forms, such as an isolated cleft mitral valve or small defects of the atrial or ventricular septa may go undetected.
Sequence similaritiesBelongs to the CRELD family.
Contains 2 EGF-like domains.
Contains 2 FU (furin-like) repeats.
- Information by UniProt
- Atrioventricular septal defect 2 antibody
- AVSD2 antibody
- CIRRIN antibody
All lanes : Anti-CRELD1 antibody (ab131286) at 1 µg/ml
Lane 1 : Heart (Human) Whole Cell Lysate - fetal normal tissue
Lane 2 : Heart (Human) Tissue Lysate - adult normal tissue
Lane 3 : Heart (Mouse) Tissue Lysate
Lane 4 : Heart (Rat) Tissue Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 45 kDa
Observed band size: 45 kDa
Additional bands at: 70 kDa (possible non-specific binding)
Exposure time: 4 minutes
This blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% Bovine Serum Albumin before being incubated with ab131286 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
IHC image of CRELD1 staining in Human heart muscle formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab131286, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ab131286 has not yet been referenced specifically in any publications.